Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    BNC105P
Show Display Options
Rank Status Study
1 Active, not recruiting BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Condition: Renal Cell Carcinoma
Interventions: Drug: Everolimus;   Drug: BNC105P
2 Recruiting BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients
Condition: Ovarian Cancer
Interventions: Drug: Carboplatin;   Drug: Gemcitabine;   Drug: BNC105P

Indicates status has not been verified in more than two years